Omeros Corp (OMER)

20.99
0.09 0.43
NASDAQ : Health Care
Prev Close 20.90
Open 20.91
Day Low/High 20.75 / 21.39
52 Wk Low/High 8.90 / 30.23
Volume 364.07K
Avg Volume 922.30K
Exchange NASDAQ
Shares Outstanding 47.80M
Market Cap 989.06M
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Omeros Closes $68.3 Million Public Offering Of Common Stock

Omeros Closes $68.3 Million Public Offering Of Common Stock

Omeros Corporation (NASDAQ: OMER) today announced that on August 18, 2017, as scheduled, it closed the underwritten public offering that was priced on August 14, 2017, relating to the sale of 3,000,000 shares of its common...

Omeros Announces Pricing Of Public Offering Of Common Stock

Omeros Announces Pricing Of Public Offering Of Common Stock

Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications...

Omeros Announces Public Offering Of Common Stock

Omeros Announces Public Offering Of Common Stock

Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications...

Omeros Data Show Continued Improvement In Patients With IgA Nephropathy Treated With OMS721

Omeros Data Show Continued Improvement In Patients With IgA Nephropathy Treated With OMS721

Omeros CorporationĀ (NASDAQ: OMER) today announced additional follow-up data from patients with immunoglobulin A (IgA) nephropathy treated with OMS721 in the Phase 2 clinical trial of glomerulonephropathy.

Omeros To Present At The 2017 Wedbush PacGrow Healthcare Conference

Omeros To Present At The 2017 Wedbush PacGrow Healthcare Conference

Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications...

3 Housing Plays With Solid Earnings

3 Housing Plays With Solid Earnings

These names are building a sound foundation for growth.

Omeros Corporation Reports Second Quarter 2017 Financial Results

Omeros Corporation Reports Second Quarter 2017 Financial Results

Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications...

FDA Grants Orphan Drug Designation To Omeros' OMS721 For Treatment Of IgA Nephropathy

FDA Grants Orphan Drug Designation To Omeros' OMS721 For Treatment Of IgA Nephropathy

Omeros Corporation (NASDAQ:OMER) today announced thatĀ OMS721 has received orphan drug designation from the U.

Omeros Corporation To Announce Second Quarter 2017 Financial Results On August 8, 2017

Omeros Corporation To Announce Second Quarter 2017 Financial Results On August 8, 2017

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter 2017 financial results for the period ended June 30, 2017, on Tuesday, August 8, 2017, after the market closes.

OMER September 15th Options Begin Trading

Investors in Omeros Corp saw new options begin trading today, for the September 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OMER options chain for the new September 15th contracts and identified one put and one call contract of particular interest.

Biotech Movers: BioCryst, Omeros, Radius Health

Biotech Movers: BioCryst, Omeros, Radius Health

BioCryst Pharmaceuticals, Omeros and Radius Health were among the were among the biotech stock movers in premarket trading on July 3.

Omeros Releases Statement In Response To Recent False Report

Omeros Releases Statement In Response To Recent False Report

Omeros Corporation (NASDAQ: OMER) stated today that it is aware of a report posted on-line by "Art Doyle," an entity or group that appears to be concealing its identity and is purportedly writing on behalf of itself or one...

These 3 Small Biotechs Have a Healthy Shot

These 3 Small Biotechs Have a Healthy Shot

Several firms hiked price targets on Portola into the $70s this week.

Give These 3 Small Biotechs a Shot

Give These 3 Small Biotechs a Shot

Several firms hiked price targets on Portola into the $70s this week.

Commit To Purchase Omeros Corp At $16, Earn 17.5% Annualized Using Options

Commit To Purchase Omeros Corp At $16, Earn 17.5% Annualized Using Options

Investors considering a purchase of Omeros Corp shares, but cautious about paying the going market price of $22.79/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2018 put at the $16 strike, which has a bid at the time of this writing of $1.80.

Biotech Stocks Finally Stage Breakthrough

Biotech Stocks Finally Stage Breakthrough

The sector decisively has pushed through upward resistance levels in place for many months.

FDA Grants Breakthrough Therapy Designation To Omeros' MASP-2 Inhibitor OMS721 For The Treatment Of IgA Nephropathy

Omeros Corporation (NASDAQ: OMER) today announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to OMS721 for the treatment of Immunoglobulin A (IgA) nephropathy.

Omeros Announces OMS721 Presentation At 54th ERA-EDTA Congress

Omeros Corporation (NASDAQ: OMER) today announced that data from the company's Phase 2 clinical trial of OMS721 for the treatment of Immunoglobulin A (IgA) nephropathy and other kidney diseases will be presented at the 54th...

3 Small Biotech Value Plays

3 Small Biotech Value Plays

These stocks will be great stories in the second half of 2017, and are significantly undervalued.

Omeros Announces Completion Of IgA Nephropathy Cohort In OMS721 Phase 2 Clinical Trial

Omeros Corporation (NASDAQ: OMER) today announced completion of the IgA nephropathy cohort and reported additional positive results from the first stage of the company's Phase 2 clinical trial of OMS721 for the treatment of...

Omeros Corporation Reports First Quarter 2017 Financial Results

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Omeros Corporation To Announce First Quarter 2017 Financial Results On May 10, 2017

Omeros Corporation (NASDAQ:OMER), today announced that the company will issue its first quarter 2017 financial results for the period ended March 31, 2017, on Wednesday, May 10, 2017, after the market closes.

We're in the Middle of the Rally

But this rally has been very much one of fits and starts.

Biotech Movers: Organovo, Endo, Omeros

Biotech Movers: Organovo, Endo, Omeros

Organovo, Endo and Omeros were among the biotech stock moves in premarket trading on Thursday.

Biotech Movers: OncoMed, Incyte, Omeros

Biotech Movers: OncoMed, Incyte, Omeros

OncoMed Pharmaceuticals, Incyte and Omeros were among the biotech stock movers in premarket trading on Monday.

Freeport McMoRan, Wix, Zions Bancorporation: 'Mad Money' Lightning Round

Freeport McMoRan, Wix, Zions Bancorporation: 'Mad Money' Lightning Round

Jim Cramer says hold off before jumping into Freeport McMoRan, Wix.com and Zions Bancorporation.

Fed Crashes the Party: Cramer's 'Mad Money' Recap (Wednesday 4/5/17)

Fed Crashes the Party: Cramer's 'Mad Money' Recap (Wednesday 4/5/17)

Jim Cramer stresses discipline here because, he says, a frothy market can quickly turn on investors.

The Dip Buyers Aren't Delivering Much Right Now

The Dip Buyers Aren't Delivering Much Right Now

The indices are holding key support, but this isn't translating into any real momentum.

TheStreet Quant Rating: D- (Sell)